Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, et al.
Clinical Journal of the American Society of Nephrology (2020) Vol. 15, Iss. 12, pp. 1715-1727
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 693
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 3075-3090
Open Access | Times Cited: 399
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 294
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 990-999
Open Access | Times Cited: 176
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Ian H. de Boer, Kamlesh Khunti, Tami Sadusky, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. 974-989
Open Access | Times Cited: 160
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, et al.
Nature Reviews Nephrology (2021) Vol. 18, Iss. 1, pp. 56-70
Closed Access | Times Cited: 153
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher, George L. Bakris, Peter Kolkhof
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3220-3234
Open Access | Times Cited: 108
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Silviu Stanciu, Emilia Rusu, Daniela Miricescu, et al.
Metabolites (2023) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 52
Combination therapy for kidney disease in people with diabetes mellitus
Daniël H. van Raalte, Petter Bjornstad, David Z.I. Cherney, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 7, pp. 433-446
Closed Access | Times Cited: 31
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Na Wang, Chun Zhang
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3086-3086
Open Access | Times Cited: 22
Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Sara H. Ksiazek, Lilio Hu, Sebastiano Andò, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4035-4035
Open Access | Times Cited: 17
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Alireza Oraii, Jeff S. Healey, Krzysztof Kowalik, et al.
European Heart Journal (2024) Vol. 45, Iss. 10, pp. 756-774
Open Access | Times Cited: 16
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
Rajiv Agarwal, Amer Joseph, Stefan D. Anker, et al.
Journal of the American Society of Nephrology (2021) Vol. 33, Iss. 1, pp. 225-237
Open Access | Times Cited: 84
Chronic Kidney Disease: Strategies to Retard Progression
Ming-Tso Yan, Chia‐Ter Chao, Shih‐Hua Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 10084-10084
Open Access | Times Cited: 78
Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
Peter Kolkhof, Amer Joseph, Ulrich Kintscher
Pharmacological Research (2021) Vol. 172, pp. 105859-105859
Open Access | Times Cited: 56
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6500-6500
Open Access | Times Cited: 41
Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Javier Morales, Yehuda Handelsman
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 2, pp. 161-170
Open Access | Times Cited: 34
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Ruolin Lv, Lili Xu, Lin Che, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 25
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
Ulrich Kintscher, Frank Edelmann
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study
Tomohiro Katsuya, Yoshito Inobe, Kazuaki Uchiyama, et al.
Hypertension Research (2024) Vol. 47, Iss. 4, pp. 835-848
Open Access | Times Cited: 12
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study
Eiichiro Yamamoto, Hiroki Usuku, Daisuke Sueta, et al.
Advances in Therapy (2024) Vol. 41, Iss. 3, pp. 1284-1303
Open Access | Times Cited: 11
Novel Insights into Diabetic Kidney Disease
Ewelina Młynarska, Dominika Buławska, Witold Czarnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10222-10222
Open Access | Times Cited: 10
Diagnosis and management of resistant hypertension
Ernesto L. Schiffrin, Naomi D.L. Fisher
BMJ (2024), pp. e079108-e079108
Open Access | Times Cited: 9
Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study
Kazuomi Kario, Hiroyuki Ohbayashi, Masami Hashimoto, et al.
Hypertension Research (2024) Vol. 47, Iss. 9, pp. 2435-2446
Open Access | Times Cited: 9
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Raja Ravender, Maria‐Eleni Roumelioti, Darren W. Schmidt, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 348-348
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top